Visium Asset Management’s Teva Pharmaceuticals TEVA Stock Holding History

Visium Asset Management’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-79,260	Closed	-$3.98M	–	179
2016 Q2	$3.98M	Sell	79,260 -269,063	-77%	-$14.3M	0.28%	101
2016 Q1	$18.6M	Sell	348,323 -121,577	-26%	-$7.13M	0.32%	76
2015 Q4	$30.8M	Buy	+469,900	New	+$29M	0.46%	42
2015 Q3	–	Sell	-200,452	Closed	-$11.8M	–	1170
2015 Q2	$11.8M	Buy	200,452 +82,962	+71%	+$5.12M	0.17%	129
2015 Q1	$7.32M	Sell	117,490 -127,574	-52%	-$7.42M	0.11%	193
2014 Q4	$14.1M	Buy	+245,064	New	+$13.7M	0.2%	93
2014 Q3	–	Sell	-14,333	Closed	-$751K	–	1207
2014 Q2	$751K	Sell	14,333 -1,998,160	-99%	-$102M	0.01%	607
2014 Q1	$106M	Buy	2,012,493 +1,951,949	+3,224%	+$90.2M	1.72%	9
2013 Q4	$2.43M	Buy	60,544 +29,734	+97%	+$1.17M	0.05%	317
2013 Q3	$1.16M	Buy	+30,810	New	+$1.2M	0.03%	392

Other funds holding TEVA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Visium Asset Management's TEVA Position: Q3 2016 in Review

Visium Asset Management sold out of Teva Pharmaceuticals (TEVA) in Q3 2016, closing a stake of 79,260 shares — an estimated $3.98M sold.

Visium Asset Management first reported a position in TEVA in Q3 2013 and held it in 10 quarters. The position peaked at $106M in Q1 2014. 796 funds tracked by Wall St. Rank hold TEVA as of Q3 2016.

Visium Asset Management reported no remaining Teva Pharmaceuticals position as of Q3 2016 after selling out during the quarter.
Visium Asset Management sold 79,260 Teva Pharmaceuticals shares in Q3 2016, an estimated $3.98M.
Visium Asset Management first reported a position in Teva Pharmaceuticals in Q3 2013 and held it in 10 quarters.
Visium Asset Management's Teva Pharmaceuticals position peaked at $106M in Q1 2014.
796 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2016.

Based on Visium Asset Management's 13F filing for Q3 2016.